Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET CC-96191.
Autorzy:
Lunn-Halbert MC; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. LaszloGS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Erraiss S; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Orr MT; Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA. Jessup HK; Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA. Thomas HJ; Immuno-Oncology Cellular Therapy Thematic Research Center, Bristol Myers Squibb, Seattle, WA 98109, USA. Chan H; Bristol Myers Squibb, San Diego, CA 92121, USA. Jahromi MA; Bristol Myers Squibb, San Diego, CA 92121, USA. Lloyd J; Bristol Myers Squibb, San Diego, CA 92121, USA. Cheung AF; Dragonfly Therapeutics, Waltham, MA 02451, USA. Chang GP; Dragonfly Therapeutics, Waltham, MA 02451, USA. Dichwalkar T; Dragonfly Therapeutics, Waltham, MA 02451, USA. Fallon D; Dragonfly Therapeutics, Waltham, MA 02451, USA. Grinberg A; Dragonfly Therapeutics, Waltham, MA 02451, USA. Rodríguez-Arbolí E; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, 41013 Seville, Spain. Lim SYT; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Kehret AR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Huo J; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Cole FM; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Scharffenberger SC; Molecular Medicine and Mechanisms of Disease (M3D) Ph.D. Program, University of Washington, Seattle, WA 98195, USA. Walter RB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA 98195, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2024 Feb 22; Vol. 16 (5). Date of Electronic Publication: 2024 Feb 22.
Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates.
Autorzy:
Petty NE; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA. Radtke S; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Fields E; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Humbert O; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Llewellyn MJ; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. LaszloGS; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Zhu H; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA. Jerome KR; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA. Walter RB; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Kiem HP; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA 98195, USA.; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.
Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.
Autorzy:
Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Bates OM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Jean SR; Eutropics Pharmaceuticals, Inc, Cambridge, MA, USA. LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Garling EE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Beddoe ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Cardone MH; Eutropics Pharmaceuticals, Inc, Cambridge, MA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (12), pp. 2990-2994. Date of Electronic Publication: 2020 Jul 04.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Bates OM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Garling EE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Beddoe ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.; Department of Pathology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2020 Apr; Vol. 189 (1), pp. e9-e13. Date of Electronic Publication: 2020 Feb 04.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Relationship between CD33 expression, splicing polymorphism, and in vitro cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE® AMG 330.
Autorzy:
LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center. Beddoe ME; Clinical Research Division, Fred Hutchinson Cancer Research Center. Godwin CD; Hematology/Oncology Fellowship Program. Bates OM; Clinical Research Division, Fred Hutchinson Cancer Research Center. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center. Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center. Walter RB; Hematology/Oncology Fellowship Program .; Department of Medicine, Division of Hematology.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2019 Feb; Vol. 104 (2), pp. e59-e62. Date of Electronic Publication: 2018 Aug 16.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Src activation decouples cell division orientation from cell geometry in mammalian cells.
Autorzy:
Sun X; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA; Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Science, Trauma Center of Postgraduate Medical School, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, P.R. China. Qi H; Key Laboratory of Systems and Control, Academy of Mathematics and Systems Science, Chinese Academy of Sciences, No. 55 Zhongguancun East Road, Beijing 100190, P.R. China. Zhang X; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA. Li L; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA; Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China. Zhang J; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA. Zeng Q; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA. LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave, Seattle, USA. Wei B; Department of General Surgery, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, P.R. China. Li T; Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, 4501 X St #3016, Sacramento, USA. Jiang J; State Key Laboratory of Trauma, Burns, and Combined Injury Research, Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing 400042, P.R. China. Mogilner A; Courant Institute, Department of Biology, New York University, 251 Mercer St, New York, USA. Fu X; Wound Healing and Cell Biology Laboratory, Institute of Basic Medical Science, Trauma Center of Postgraduate Medical School, Chinese PLA General Hospital, 28 Fu Xing Road, Beijing 100853, P.R. China. Electronic address: . Zhao M; Institute for Regenerative Cures, University of California, Davis, CA, USA; Department of Dermatology, University of California, Davis, CA, USA; Department of Ophthalmology, University of California, Davis, CA, USA. Electronic address: .
Pokaż więcej
Źródło:
Biomaterials [Biomaterials] 2018 Jul; Vol. 170, pp. 82-94. Date of Electronic Publication: 2018 Apr 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Autorzy:
LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Alonzo TA; Department of Biostatistics, University of Southern California, Los Angeles, CA, USA.; Children's Oncology Group, Monrovia, CA, USA. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Kentsis A; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Medical College of Cornell University, New York, NY, USA. Gerbing RB; Children's Oncology Group, Monrovia, CA, USA. Wang YC; Children's Oncology Group, Monrovia, CA, USA. Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Raimondi SC; Children's Oncology Group, Monrovia, CA, USA.; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. Hirsch BA; Children's Oncology Group, Monrovia, CA, USA.; Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA. Gamis AS; Children's Oncology Group, Monrovia, CA, USA.; Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA. Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.; Children's Oncology Group, Monrovia, CA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. .; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. .; Department of Epidemiology, University of Washington, Seattle, WA, USA. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2016 Nov 30; Vol. 9 (1), pp. 133. Date of Electronic Publication: 2016 Nov 30.
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Autorzy:
LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Alonzo TA; Department of Biostatistics, University of Southern California, Los Angeles, CA, USA.; Children's Oncology Group, Monrovia, CA, USA. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Kentsis A; Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Medical College of Cornell University, New York, NY, USA. Gerbing RB; Children's Oncology Group, Monrovia, CA, USA. Wang YC; Children's Oncology Group, Monrovia, CA, USA. Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. Raimondi SC; Children's Oncology Group, Monrovia, CA, USA.; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. Hirsch BA; Children's Oncology Group, Monrovia, CA, USA.; Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA. Gamis AS; Children's Oncology Group, Monrovia, CA, USA.; Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA. Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA.; Children's Oncology Group, Monrovia, CA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA, 98109-1024, USA. .; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. .; Department of Epidemiology, University of Washington, Seattle, WA, USA. .
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
Autorzy:
Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. Newhall KJ; Amgen, Inc., Seattle, Washington, United States of America. Sinclair AM; Amgen, Inc., Thousand Oaks, California, United States of America. Frankel SR; Amgen, Inc., Rockville, Maryland, United States of America. Kischel R; Amgen Research (Munich) GmbH, Munich, Germany. Chen G; Amgen, Inc., Seattle, Washington, United States of America. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America; Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington, United States of America; Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Aug 25; Vol. 10 (8), pp. e0135945. Date of Electronic Publication: 2015 Aug 25 (Print Publication: 2015).
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Autorzy:
LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2015 Aug 21; Vol. 5, pp. e340. Date of Electronic Publication: 2015 Aug 21.
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.
Autorzy:
Walter RB; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Hematology, Department of Medicine, University of Washington, Seattle, WA, USA [3] Department of Epidemiology, University of Washington, Seattle, WA, USA. LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Lionberger JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Pollard JA; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA. Harrington KH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Gudgeon CJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Rafii S; Department of Genetic Medicine, Weill Cornell Medical College, New York, NY, USA. Meshinchi S; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA. Appelbaum FR; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Bernstein ID; 1] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA [2] Department of Pediatrics, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Leukemia [Leukemia] 2014 Oct; Vol. 28 (10), pp. 1969-77. Date of Electronic Publication: 2014 Mar 18.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Autorzy:
LaszloGS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Estey EH; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: .
Pokaż więcej
Źródło:
Blood reviews [Blood Rev] 2014 Jul; Vol. 28 (4), pp. 143-53. Date of Electronic Publication: 2014 Apr 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies